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Direct-to-consumer (DTC) DNA testing has grown from contentious beginnings into a global
industry, by providing a wide range of personal genomic information directly to its clients.
These companies, typified by the well-established 23andMe, generally carry out a gene-
chip analysis of single-nucleotide polymorphisms (SNPs) using DNA extracted from a saliva
sample. These genetic data are then assimilated and provided direct to the client, with
varying degrees of interpretation. Although much debate has focused on the limitations
and ethical aspects of providing genotypes for disease risk alleles, the provision of phar-
macogenetic results by DTC companies is less studied. We set out to evaluate current
DTC pharmacogenetics offerings, and then to consider how these services might best
evolve and adapt in order to play a potentially useful future role in delivery of personalized
medicine.
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INTRODUCTION
The provision of direct-to-consumer (DTC) genotyping services
gives patients access to personal genetic information that is often
of uncertain value, and that the majority of medical profes-
sionals are not sufficiently confident of handling (Stanek et al.,
2012). Despite the contentious beginnings of these services and
debates about the value of the information they provide (Platt,
2009; Vashlishan Murray et al., 2010), it is fair to suggest that
DTC companies have played an important role in raising pub-
lic awareness around genetics, empowering individuals to seek
more knowledge about their own genomes and enabling them
to encourage their doctors to also consider this information. It
seems likely these companies will remain a significant force as
providers of genome information to the public, and it is conceiv-
able that they will evolve to become major players in the healthcare
setting.
Setting aside debates around the value and dangers of geno-
typing risk alleles for complex disease, we focus here on the
pharmacogenetic information currently provided by DTC com-
panies, and assess the value and limitations of this information.
We have primarily depended on information gleaned from com-
pany websites, and we have adopted a rather broad definition of
DTC pharmacogenetics in order to encompass a wide range of
services. Companies were deemed to be “DTC” if they provide a
mechanism for the consumers to directly order the tests advertised
online, either with or without prescription by a physician. The
list we have developed (available from http://www.otago.ac.nz/
christchurch/research/carneycentre/publications/otago033875) is
largely a subset of that released by the Genetics and Pub-
lic Policy Centre (Dvoskin, 2011), with a few additions that
we have come across in the review process. The listed com-
panies employ two general approaches, one which is purely
DTC and does not involve consultation with independent doc-
tors (23andMe, GenePlanet, Matrix Genomics, Theranostics Lab),
and one that does (Genelex, Kimball Genetics, Navigenics, and
Pathway Genomics). The list is not exhaustive and is pri-
marily meant to illustrate the current state of DTC pharma-
cogenetic testing services, although the landscape is changing
rapidly.
The types of DTC pharmacogenetic tests offered encompass
a wide range, with certain drug-gene pairs being exclusively
offered by some companies (Table 1). We have excluded tests
that are not strictly related to clinical pharmacogenetics: alco-
hol consumption, smoking and risk of esophageal cancer, caf-
feine metabolism, and heroin addiction. In the majority of cases
selection or inclusion of pharmacogenes or markers will be con-
strained by the genotyping platform employed. PCR-based meth-
ods allow analysis of a relatively small number of variants, but
are very easily customized to incorporate new tests. Chip-based
platforms interrogate very large numbers of variants, but tend
to be less adaptable due to production costs. Some companies,
such as 23andMe, employ a gene-chip genotyping approach that
provides genome-wide targeted probing of about one million
single-nucleotide polymorphisms (SNPs), and others, such as
Genelex, use more readily customizable PCR-based genotyping
platforms.
CURRENT DTC PHARMACOGENETICS OFFERINGS
Our review of DTC pharmacogenetic testing services illustrated
that current offerings in the pharmacogenomics space are patchy
and quite limited. These limitations occur at the level of the specific
genes selected for genotyping, which in many cases is governed
by the technology platform used (as mentioned above), and in
the range of gene variants or alleles that are genotyped. These
www.frontiersin.org August 2012 | Volume 3 | Article 152 | 1
Chua and Kennedy DTC pharmacogenetics
Ta
b
le
1
|R
an
ge
o
f
D
T
C
p
h
ar
m
ac
o
ge
n
et
ic
te
st
s.
P
h
ar
m
ac
o
ge
n
et
ic
tr
ai
t
23
an
d
M
e
G
en
el
ex
G
en
eP
la
n
et
K
im
b
al
l
G
en
et
ic
s
M
at
ri
x
G
en
o
m
ic
s
N
av
ig
en
ic
s
Pa
th
w
ay
G
en
o
m
ic
s
T
h
er
an
o
st
ic
s
La
b
A
D
V
E
R
S
E
D
R
U
G
R
E
A
C
T
IO
N
S
(A
D
R
S
)
A
ba
ca
vi
r
hy
pe
rs
en
si
tiv
ity
H
LA
-B
*5
70
1
rs
23
95
02
9
H
LA
-B
*5
70
1
rs
23
95
02
9
U
nk
no
w
n
A
m
in
og
ly
co
si
de
-in
du
ce
d
ot
ot
ox
ic
ity
U
nk
no
w
n
C
ar
ba
m
az
ep
in
e
hy
pe
rs
en
si
tiv
ity
H
LA
-B
*1
50
2
rs
28
44
68
2
rs
39
09
18
4
U
nk
no
w
n
Fl
ox
ac
ill
in
-in
du
ce
d
he
pa
to
to
xi
ci
ty
H
LA
-B
*5
70
1
rs
23
95
02
9
H
LA
-B
*5
70
1
rs
23
95
02
9
Fl
uo
ro
ur
ac
il
to
xi
ci
ty
D
P
Y
D
*2
A
D
P
Y
D
al
le
le
D
P
Y
D
*2
A
In
te
rf
er
on
-in
du
ce
d
th
ro
m
bo
cy
to
pe
ni
a
IT
PA
/D
D
R
G
K
1
rs
61
39
03
0
Ir
in
ot
ec
an
to
xi
ci
ty
U
G
T1
A
1*
28
U
G
T1
A
1*
28
rs
10
92
93
02
Lu
m
ira
co
xi
b-
in
du
ce
d
he
pa
to
to
xi
ci
ty
H
LA
al
le
le
s
rs
31
29
90
0
M
et
ho
tr
ex
at
e
to
xi
ci
ty
U
nk
no
w
n
O
ra
lc
on
tr
ac
ep
tiv
es
,h
or
m
on
e
re
pl
ac
em
en
t
th
er
ap
y,
an
d
ris
k
of
ve
no
us
th
ro
m
bo
em
bo
lis
m
(V
TE
)
Fa
ct
or
V
Le
id
en
Pr
ot
hr
om
bi
n
G
20
21
0A
va
ria
nt
U
nk
no
w
n
Po
st
op
er
at
iv
e
na
us
ea
an
d
vo
m
iti
ng
(P
O
N
V
)
D
R
D
2
Ta
q1
A
P
se
ud
oc
ho
lin
es
te
ra
se
de
fic
ie
nc
y
B
C
H
E
va
ria
nt
s:
A
sp
70
G
ly
(A
)
Th
r2
43
M
et
(F
1)
G
ly
39
0V
al
(F
2)
B
C
H
E
va
ria
nt
s:
A
sp
70
G
ly
(A
)
B
C
H
E
*5
39
T
(C
on
tin
ue
d)
Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics August 2012 | Volume 3 | Article 152 | 2
Chua and Kennedy DTC pharmacogenetics
Ta
b
le
1
|C
o
n
ti
n
u
ed
P
h
ar
m
ac
o
ge
n
et
ic
tr
ai
t
23
an
d
M
e
G
en
el
ex
G
en
eP
la
n
et
K
im
b
al
l
ge
n
et
ic
s
M
at
ri
x
ge
n
o
m
ic
s
N
av
ig
en
ic
s
Pa
th
w
ay
ge
n
o
m
ic
s
T
h
er
an
o
st
ic
s
La
b
R
ib
av
iri
n-
in
du
ce
d
an
em
ia
IT
PA
va
ria
nt
:
Pr
o3
2T
hr
S
el
ec
tiv
e
se
ro
to
ni
n
re
up
ta
ke
in
hi
bi
to
rs
(S
S
R
I)
an
d
se
xu
al
dy
sf
un
ct
io
n
H
TR
2A
va
ria
nt
S
ta
tin
-in
du
ce
d
m
yo
pa
th
y
S
LC
O
1B
1*
5
C
O
Q
2
va
ria
nt
S
LC
O
1B
1*
5
U
nk
no
w
n
S
LC
O
1B
1*
5
Th
io
pu
rin
e
to
xi
ci
ty
TP
M
T*
2
TP
M
T*
3A
,*
3B
,
*3
C
D
R
U
G
E
FF
IC
A
C
Y
A
nt
id
ep
re
ss
an
ts
A
B
C
B
1
rs
20
32
58
3
C
Y
P
2D
6*
1-
*1
5
C
Y
P
2D
6*
17
,*
41
A
B
C
B
1
rs
20
32
58
3
C
Y
P
2D
6
al
le
le
s,
C
Y
P
2C
19
*2
-*
8,
CY
P
2C
19
*1
7
A
sp
iri
n
an
d
st
ro
ke
;m
yo
ca
rd
ia
l
in
fa
rc
tio
n
(M
I)
IT
G
B
3
va
ria
nt
:
Le
u3
3P
ro
B
et
a-
bl
oc
ke
r
an
d
he
ar
t
fa
ilu
re
A
D
R
B
1
va
ria
nt
:
A
rg
38
9G
ly
A
D
R
B
1
va
ria
nt
:
A
rg
38
9G
ly
G
R
K
5
va
ria
nt
:
ln
41
Le
u
B
et
a-
bl
oc
ke
r
an
d
hy
pe
rt
en
si
on
C
lo
pi
do
gr
el
an
d
st
ro
ke
;M
I
C
Y
P
2C
19
*2
-*
4
C
Y
P
2C
19
*8
,*
17
C
Y
P
2C
19
*2
-*
8
CY
P
2C
19
*1
7
C
Y
P
2C
19
*2
-*
8,
CY
P
2C
19
*1
7
C
Y
P
2C
19
*2
,*
3
U
nk
no
w
n
C
Y
P
2C
19
*2
,*
3
C
Y
P
2C
19
*1
7
In
te
rf
er
on
-α
/r
ib
av
iri
n
an
d
he
pa
tit
is
C
IL
28
B
rs
80
99
91
7
In
te
rf
er
on
-β
an
d
m
ul
tip
le
sc
le
ro
si
s
G
P
C
5
rs
79
87
67
5
M
et
fo
rm
in
an
d
ty
pe
2
di
ab
et
es
m
el
lit
us
AT
M
rs
45
85
N
al
tr
ex
on
e
an
d
al
co
ho
ld
ep
en
de
nc
e
O
P
R
M
1
va
ria
nt
:
A
sn
40
A
sp
(C
on
tin
ue
d)
www.frontiersin.org August 2012 | Volume 3 | Article 152 | 3
Chua and Kennedy DTC pharmacogenetics
Ta
b
le
1
|C
o
n
ti
n
u
ed
P
h
ar
m
ac
o
ge
n
et
ic
tr
ai
t
23
an
d
M
e
G
en
el
ex
G
en
eP
la
n
et
K
im
b
al
l
G
en
et
ic
s
M
at
ri
x
G
en
o
m
ic
s
N
av
ig
en
ic
s
Pa
th
w
ay
G
en
o
m
ic
s
T
h
er
an
o
st
ic
s
La
b
S
ild
en
afi
la
nd
er
ec
til
e
dy
sf
un
ct
io
n
G
N
B
3
va
ria
nt
:
S
er
27
5S
er
S
ta
tin
s
an
d
M
I
K
IF
6
va
ria
nt
:
Tr
p7
19
A
rg
A
po
E
2,
E
3,
or
E
4
al
le
le
U
nk
no
w
n
Ta
m
ox
ife
n
an
d
br
ea
st
ca
nc
er
C
Y
P
2D
6*
1-
*1
5
C
Y
P
2D
6*
17
,*
41
C
Y
P
2D
6
C
Y
P
2C
19
*1
7
Tr
ip
ta
ns
an
d
m
ig
ra
in
e
G
N
B
3
va
ria
nt
:
S
er
27
5S
er
W
ar
fa
rin
se
ns
iti
vi
ty
V
KO
R
C
1*
2
C
Y
P
2C
9*
2,
*3
V
KO
R
C
1*
2
C
Y
P
2C
9*
2
-*
8,
*1
1,
*1
3
V
KO
R
C
1*
2
C
Y
P
2C
9*
2,
*3
V
KO
R
C
1*
2
C
Y
P
2C
9*
2,
*3
V
KO
R
C
1*
2
C
Y
P
2C
9*
2,
*3
,*
5,
*6
C
Y
P
4F
2*
3
G
C
X
va
ria
nt
V
KO
R
C
1*
2
C
Y
P
2C
9*
2,
*3
C
Y
P
4F
2*
3
U
nk
no
w
n
V
KO
R
C
1*
2
C
Y
P
2C
9*
2,
*3
S
ha
de
d
bo
xe
s
in
di
ca
te
th
at
th
e
te
st
s
ar
e
no
to
ffe
re
d
by
th
e
co
m
pa
ni
es
.P
ha
rm
ac
og
en
et
ic
tr
ai
ts
w
ith
cl
ea
rF
D
A
re
co
m
m
en
da
tio
ns
ar
e
un
de
rli
ne
d.
M
at
rix
G
en
om
ic
s
al
so
ge
no
ty
pe
s
C
Y
P
3A
5;
G
en
el
ex
al
so
of
fe
rs
te
st
s
fo
r
C
Y
P
1A
2
an
d
N
AT
2.
Frontiers in Pharmacology | Pharmacogenetics and Pharmacogenomics August 2012 | Volume 3 | Article 152 | 4
Chua and Kennedy DTC pharmacogenetics
limitations are important because they can influence interpre-
tation of results and the accuracy of predictions based on the
data (Ng et al., 2009). Genotype-based classification of meta-
bolic status can be clouded by the existence of multiple alleles
that dictate enzymatic function, especially when assignment of
metabolic status depends largely on the presence or absence of
loss-of-function alleles. Pitfalls arise when defective alleles that
are not typed are, in fact, present (PharmGKB, 2011). For exam-
ple, about 30 defective CYP2C19 alleles have been identified to
date, and the prevalence of these alleles is ethnicity-dependent.
All companies only measure a proportion of the alleles in their
CYP2C19 tests and inclusion of alleles differs between compa-
nies (Table 1). This could lead to varying degrees of test accu-
racy across different ethnic groups. Genetic tests that measure
only CYP2C19∗2 and ∗3 alleles would correctly identify approx-
imately 88% of Caucasian poor metabolizers (PMs), but nearly
100% of Oriental PMs. Typing of more defective alleles such
as CYP2C19∗4 would improve the test accuracy among Cau-
casians, but have no additional benefits for patients of other
ancestries (de Morais et al., 1994; Ferguson et al., 1998; Ibeanu
et al., 1998; Sim, 2011). Moreover, other factors such as gene
dosage, modifier genes, drug–drug interactions, and relevant envi-
ronmental effects could also affect the accuracy of phenotype
prediction.
The influences of ethnicity are also notable when the allele-
or SNP-phenotype association is used to predict the development
of an adverse drug reaction (ADR) or response to a drug. This
is an area in which current evidence varies considerably across
ethnic groups. For instance, HLA-B∗1502 allele is a strong predic-
tor of carbamazepine-induced severe cutaneous adverse reactions
(SCARs) in Han Chinese patients, but it is absent in other pop-
ulations such as Caucasians (Chung et al., 2004; McCormack
et al., 2011). Another less extreme example is the response to
interferon-α/ribavirin which is independently influenced by a
number of SNPs near the IL28B gene region. Two SNPs, namely
rs12979860 and rs8099917, have exhibited the strongest signals
in several studies involving patients of different ancestries (Lange
and Zeuzem, 2011). rs12979860, however, has been found to be
less reliable in Japanese patients (Ito et al., 2011), suggesting
that data from genotyping a single SNP may not be sufficiently
generalizable across populations – a limitation often acknowl-
edged by DTC companies in their reports. Of the companies
surveyed only 23andMe offers the IL28B test, using the SNP
rs8099917 to classify individuals into various response categories.
As noted, many DTC companies are restrained by their chip-
based genotyping platforms and currently available evidence of
SNP-phenotype association, and are therefore less capable of tun-
ing their tests to account for the ethnic diversity of their global
customer base.
The categorization of metabolic capacity is also an impre-
cise process, complicated by lack of a consensual classification
system which takes into account various factors that may influ-
ence enzymatic function. The categories of PMs, intermediate
(IMs), extensive (EMs), or ultra-metabolizers (UMs) are rarely
discrete. Rather, they represent a continuous spectrum of meta-
bolic function with significant inter-group overlap. Phenotypic
prediction and classification based on a complex array of CYP2D6
variants, which give rise to both allele-specific and substrate-
specific effects on enzymatic activity, is particularly daunting.
Genelex, for instance, employs a multiplex PCR approach to
detect CYP2D6 gene duplication and 17 alleles; the diplotypes
are subsequently classified into PM, IM, EM, or UM. However,
this seemingly comprehensive test has two important caveats.
First, classifying the multitude of CYP2D6 allelic combinations
into just four metabolic categories and applying these universally
to CYP2D6 substrates can be rather simplistic. Second, default
assignment of functional gene duplication can lead to overes-
timation of CYP2D6 activity when non-functional or reduced-
function alleles are duplicated (Gaedigk et al., 2007a); or when
the duplication is a false positive as a result of undetected
hybrid alleles (Black et al., 2012). These problems are not spe-
cific to DTC companies, as they are an ongoing issue for the
entire pharmacogenomics community. For example, although
an activity score system has been proposed to account for the
nuances in enzymatic activity conferred by different CYP2D6
diplotypes, thereby producing more refined prediction of meta-
bolic status (Gaedigk et al., 2007b), no consensus has yet been
reached with regard to the best classification system (Kirchheiner,
2008), and there is evidence to suggest that the traditional sys-
tem may perform equally well in certain instances (Lötsch et al.,
2009).
The most important issue surrounding DTC pharmacogenet-
ics is a lack of unequivocal clinical value for many of the tests
on offer. Marketing pharmacogenetic data which are still debat-
able could be premature; however, where this is made clear in
the report the information provided could be of some educa-
tional value. For the purposes of this review we used as a guide to
“actionable” tests any recommendations in the US Food and Drug
Administration (FDA) drug labels, and guidelines from the Dutch
Pharmacogenetics Working Group [DPWG; Swen et al., 2011;
PharmGKB, 2012; US Food and Drug Administration (FDA),
2012]. Guidelines developed by the Clinical Pharmacogenetics
Implementation Consortium (CPIC) are underway and yet to
be completed (Relling and Klein, 2011) therefore these guide-
lines have not been used in our analysis. FDA-approved drug
labels containing information on pharmacogenomics biomark-
ers were screened in an attempt to identify drug-gene pairs
for which pharmacogenetic data may provide an “actionable”
outcome. Out of the 112 FDA drug-gene pairs, only 30 are
good candidates for DTC testing as they are provided with
pharmacogenetics-based recommendations in the product inserts.
These recommendations vary from specific dose adjustments,
or drug avoidance, to vague dosage guidelines, which typically
involve dose reduction of uncertain magnitude (Table 2). Thirty-
three drug-gene pairs were considered irrelevant in the DTC
setting: 27 are associated with cancer genetics, 5 with congen-
ital disorders, and 1 with determination of HIV-1 strain. For
the remaining 49 drug-gene pairs, pharmacogenetics-based rec-
ommendations are either absent or irrelevant. Testing for this
group of 82 drug-gene pairs is therefore probably of little clinical
value.
Currently for most of the drug-gene pairs listed on the
FDA website [US Food and Drug Administration (FDA), 2012],
genetic screening is recommended but not required by FDA
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Table 2 | Drug-gene pairs with therapeutic recommendations in FDA drug labels and the Dutch Pharmacogenetics Working Group (DPWG)
guidelines.
Treatment modifications to avoid ADRs Treatment modifications based on metabolic status Ambiguous recommendations
FDA-only FDA-only DPWG-only (cont’d) FDA-only
Carbamazepine/HLA-B*1502 Celecoxib/CYP2C9 Metoprolol/CYP2D6 Azathioprine/TPMT
Dextromethorphan and quinidine/CYP2D6 Clobazam/CYP2C19 Nortriptyline/CYP2D6 Carisoprodol/CYP2C19
Pimozide/CYP2D6 Iloperidone/CYP2D6 Omeprazole/CYP2C19 Cevimeline/CYP2D6
Rasburicase/G6PD Tetrabenazine/CYP2D6 Oxycodone/CYP2D6 Chloroquine/G6PD
Thioridazine/CYP2D6 Warfarin/CYP2C9 Pantoprazole/CYP2C19 Clopidogrel/CYP2C19
Warfarin/VKORC1 Paroxetine/CYP2D6 Clozapine/CYP2D6
DPWG-only Phenprocoumon/CYP2C9 Flurbiprofen/CYP2C9
Estrogen-containing oral contraceptives DPWG-only Phenprocoumon/VKORC1 Fluvoxamine/CYP2D6
(OCs)/Factor V Leiden Acenocoumarol/CYP2C9 Phenytoin/CYP2C9 Irinotecan/UGT1A1
Tegafur and uracil/DPYD Acenocoumarol/VKORC1 Propafenone/CYP2D6 Mercaptopurine/TPMT
Amitriptyline/CYP2D6 Risperidone/CYP2D6 Phenytoin/HLA-B*1502
Both FDA and DPWG Azathioprine/TPMT Sertraline/CYP2C19 Thioguanine/TPMT
Abacavir/HLA-B*5701 Clomipramine/CYP2D6 Tamoxifen/CYP2D6
Capecitabine/DPYD Clopidogrel/CYP2C19 Thioguanine/TPMT
Fluorouracil/DPYD Doxepin/CYP2D6 Tramadol/CYP2D6
Escitalopram/CYP2C19 Venlafaxine/CYP2D6
Esomeprazole/CYP2C19 Voriconazole/CYP2C19
Lansoprazole/CYP2C19 Zuclopenthixol/CYP2D6
Flecainide/CYP2D6
Haloperidol/CYP2D6 Both FDA and DPWG
Imipramine/CYP2C19 Aripriprazole/CYP2D6
Imipramine/CYP2D6 Atomoxetine/CYP2D6
Irinotecan/UGT1A1 Citalopram/CYP2C19
Mercaptopurine/TPMT Codeine/CYP2D6
(PharmGKB, 2012). Only a small proportion of the drug-gene
pairs tested by DTC companies are likely to have a significant
impact on clinical intervention (Table 1). For many drug-gene
pairs, consensus guidelines have yet to be established, as evi-
denced by little overlap between FDA and DPWG in their lists
of useful drug-gene pairs (Table 2). Dosing based on thiopurine
methyltransferase (TPMT) activity (testing offered by Navigen-
ics), for example, is somewhat ambiguous. While DPWG pro-
vides clear-cut dosage guidelines for poor methylator pheno-
types, FDA is still uncertain in this regard [Swen et al., 2011;
US Food and Drug Administration (FDA), 2012]. The value
of pharmacogenetic data provided by DTC companies is there-
fore limited by lack of effective guidelines for test interpretation,
which is of course, a much wider problem in pharmacogenet-
ics. The approaches taken by the CPIC, and other bodies, should
steadily lead to improvements in this situation (Relling and Klein,
2011).
WHAT IS THE FUTURE FOR DTC
PHARMACOGENETICS/PHARMACOGENOMICS?
As we have shown, current DTC pharmacogenetics offerings are
significantly limited in scope and utility. That said, it is likely these
companies are here to stay and it is worth considering how they
may look in the future. Several points are worth considering, the
first of which relates to the pace of change in genomics technology.
The rapid evolution of next generation sequencing technologies
has ushered in an era of “personal genomics” (McGuire et al.,
2007). As the cost of generating human genome sequences has
plummeted, many companies are gearing up to provide, or are
already providing, whole human genome sequences, or the more
targeted subset of all exons in the genome (the exome). The
first signs of transition by DTC companies to the use of genome
sequence information rather than genotyping of specific loci are
apparent, and it seems inevitable that others will follow this trend.
In September 2011, 23andMe announced a pilot project aimed
at providing raw exome data to its existing customers, for a
price of USD999 (23andMe, 2011). Transition from chip-based
or candidate-gene typing to exome sequencing will provide much
more detailed pharmacogenetic data and could allow interroga-
tion of multiple markers to add predictive power. Certainly, it
should be possible to provide a fairly complete profile of phar-
macogenetic variants with known functional effects, but of course
many rare variants of unknown function will also be detected and
sorting signals from noise will be a significant problem. In addi-
tion, it is still difficult to distil accurate copy number variation
(CNV) data from sequencing data (Zhang et al., 2011), and until
this becomes a more precise process, it will be difficult to provide
accurate information on CNVs in pharmacogenes – with CYP2D6
as the paradigmatic pharmacogene whose activity is affected by
CNV.
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A major challenge to the application of whole genome data
will be the high load of rare variants apparent in human genomes
(Nelson et al., 2012). Genotype-phenotype correlations are imper-
fect even for common pharmacogenetic variants and interpreting
the clinical relevance of rare variants will be crucially important
to extract maximum value from personal genomes. Resolving this
issue will likely require the application of new bioinformatics-
and laboratory-based functional screens, but even with improved
methods it is probable that prediction of phenotype based
on personal genome data will always carry with it a level of
uncertainty.
To apply exome or whole genome sequencing (WGS) in
the clinical setting, the standard of its performance must be
at a level that is equivalent to other diagnostic tests. In the
United States, compliance with Clinical Laboratory Improvement
Amendments (CLIA) is considered to be a hallmark of qual-
ity for laboratory tests (Frueh et al., 2011; Spencer et al., 2011).
Most currently available DTC genetic tests are conducted in lab-
oratories with CLIA or equivalent levels of certification. DTC
exome sequencing services should also meet similar regulatory
requirements. In order to accommodate the global nature and
novel features of the service, modernization of national regu-
lations and establishment of an international certification sys-
tem have been suggested (Frueh et al., 2011; Hauskeller, 2011).
Ensuring the diagnostic validity of DTC results in this way
could add confidence for the consumer and may position DTC
testing companies for a more expansive role in the healthcare
setting.
Many critics of DTC genetic testing focus on the reduced
role for medical professionals as gatekeepers to complex genetic
information (Lenzer and Brownlee, 2008; Anonymous, 2008).
However, health care professionals are generally ill-prepared
for incorporating pharmacogenetics into their practice (Stanek
et al., 2012). It is likely that the activities of DTC companies
are educating consumers about genetics and pharmacogenet-
ics, and these consumers will in turn indirectly influence and
educate their physicians. Indeed, the models for genome data
collection, interpretation, and dissemination adopted by DTC
companies, particularly their use of web-based tools for pro-
viding continually updated information to clients, can be seen
as key components of genomics-based health care (Platt, 2009)
and may offer a viable route for the integration of genomic
and pharmacogenomic data into more traditional health care
structures.
Few health systems are likely to adopt routine, widespread
pharmacogenomic testing in the near future. This may provide
the opportunity for DTC pharmacogenetics companies to flour-
ish. While many arguments in pharmacogenetics center on the
cost-benefit analysis of tests, and the mechanisms for reimbursing
testing costs, DTC genetics may help to resolve these debates. It has
even been speculated that the affordability of WGS would rapidly
improve to a point where genotyping could be regarded as essen-
tially free (Altman, 2011). When patients turn up in a clinic with
a full pharmacogenetics profile, obtained from a DTC company
and performed in a CLIA-certified laboratory, surely the clinician
ought to consider integrating this knowledge in their treatment
plans? The obvious caveats on this scenario, which are relatively
specific to the DTC companies, include the danger of overstating
the value of such tests, and the need to follow clinical guidelines or
rely on intelligent and thorough assessments of the evidence base,
wherever possible.
CONCLUSION
The development of DTC genetic testing has caused considerable
controversy, particularly with regard to genes that influence risk of
disease. Although perhaps less controversial, the pharmacogenet-
ics offerings of DTC companies also have problems, although the
worst of these are precisely those which challenge all practitioners
in this field. Two primary problems are the quality of evidence that
links genetic variants to functional effects, and the clinical utility
of genotypes for specific genes. We anticipate that both of these
issues will gradually resolve to a point at which most common,
clinically useful gene variants have been identified and incorpo-
rated into treatment guidelines. The high level of rare variants
observed in human genomes will remain an issue (Nelson et al.,
2012), and collectively these may represent a significant pharma-
cogenetic load in the population that will be more difficult to
understand.
Despite their controversial origins DTC companies deserve
credit for at least two things. The first is that their activities have
raised public awareness of genome analysis and its relevance to
therapeutic drug responses. The second is that these companies
offer a route to bringing pharmacogenomic data to the table,
empowering patients who may feel the need to obtain such data,
and enabling them to discuss it with their clinician – which at a
minimum may be a useful, two-way learning opportunity. In this
situation the patient is taking on a more active role by “initiating”
testing and educating and encouraging the physician to consider
and perhaps act on this information.
Relatively inflexible genotyping technologies, at present, con-
strain the range of pharmacogenetic data that is generated, and
our survey revealed that the current DTC pharmacogenetics test
offerings are patchy and of limited clinical value. However, it is
likely these companies will be early adopters of exome and whole
genome services, and already we are seeing transition to these
kinds of datasets for clients. The companies active in this space
are experienced at providing genomic information to their clients
via web interfaces in an appealing, understandable, and secure for-
mat which is well suited to the ongoing updating of interpretive
material – an essential need in a field where the evidence base
is continually growing and changing. This may well prove to be
an edge that allows such companies to compete effectively in the
provision of whole genome or exome data not only in a DTC
environment, but also in the clinical setting. The next few years
may see some significant changes in traditional clinical laboratory
testing models, with DTC companies offering a relatively low cost
approach to pharmacogenomic data provision. Over this period
most companies are also likely to transition to exome or whole
genome methods for generating personal genome data, with a
corresponding increase in the range and value of pharmacoge-
nomic data provided. It will be of great interest to see how this
innovative and oft maligned industry evolves and grows, and to
see what impact this has on the understanding and routine use of
pharmacogenomic knowledge.
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